Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 17/20 | 0.43 |
| ▸ | MDM4 | O15151 | 13/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14375817 | 1.00 | CRHBP (0.44) | CRHBPCRHR2MDM2MDM4KMT2A | |
| SCHEMBL30225606 | 0.86 | CRHBP (0.58) | CRHBPCRHR2MDM2MDM4KMT2A | |
| SCHEMBL2395864 | 0.86 | CRHBP (0.58) | CRHBPCRHR2MDM2MDM4KMT2A | |
| SCHEMBL30225589 | 0.86 | CRHBP (0.58) | CRHBPCRHR2MDM2MDM4KMT2A | |
| SCHEMBL30225612 | 0.86 | CRHBP (0.58) | CRHBPCRHR2MDM2MDM4KMT2A | |
| SCHEMBL23842064 | 0.86 | CRHBP (0.58) | CRHBPCRHR2MDM2MDM4KMT2A | |
| SCHEMBL2393838 | 0.86 | CRHBP (0.58) | CRHBPCRHR2MDM2MDM4KMT2A | |
| SCHEMBL12258915 | 0.84 | MDM2 (0.50) | CRHBPCRHR2MDM2MDM4KMT2A | |
| SCHEMBL15701400 | 0.84 | MDM2 (0.50) | CRHBPCRHR2MDM2MDM4KMT2A | |
| SCHEMBL15701402 | 0.84 | MDM2 (0.50) | CRHBPCRHR2MDM2MDM4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051279-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| US-9051279-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| US-9051279-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| EP-2721008-B1 | HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES AS P53 (MDM2 OR MDM4) INHIBITORS | NOVARTIS AG (CH) | 2015-04-29 | — | — | EP | disclosed |
| EP-2721008-B1 | HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES AS P53 (MDM2 OR MDM4) INHIBITORS | NOVARTIS AG (CH) | 2015-04-29 | — | — | EP | disclosed |
| US-8859535-B2 | Hydroxy substituted isoquinolinone derivatives | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| US-8859535-B2 | Hydroxy substituted isoquinolinone derivatives | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| US-8859535-B2 | Hydroxy substituted isoquinolinone derivatives | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| EP-2516009-B1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-20140135306-A1 | HDYROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| US-20130281473-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130281473-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-8440693-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8440693-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8440693-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| WO-2012175520-A1 | HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | disclosed |
| EP-2516009-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | MDM4, MDM2, TP53 | CRHBP 3810/4885CRHR2 3142/4885MDM2 2/4885 |
| US-20130281473-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | MDM4, MDM2, TP53 | CRHBP 3810/4885CRHR2 3142/4885MDM2 2/4885 |
| US-20140135306-A1 | HDYROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES | MDM4, MDM2, TP53 | CRHBP 3581/4885CRHR2 4026/4885MDM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.